You are interested in Resolve Biosciences? Great! This is the first step to get in touch!
There is no suitable open position among our job offers that fits to your skillset but you feel you can contribute to our success? In this case please send us your application documents stating in the cover letter your strengths and where you see yourself being beneficial to us!
We are always looking for great minds and are glad to receive your application!
We will review your profile carefully and will get in touch with you.
We are looking forward to get to know each other!
At Resolve Biosciences, we believe that diversity, equity, and inclusion are essential to our success. We welcome applicants of all genders, ethnicities, nationalities, religions, abilities, and backgrounds to apply for our open positions. We are committed to creating a workplace where everyone feels valued, respected, and supported.
We are a young, dynamic life science company with a focus on molecular pathology. Since 2020, we have been working on the fields of application and developing our own Molecular Cartography™ technology, which can be used to visualize gene and protein expression in tissue sections at the subcellular level in high spatial resolution.
Every individual counts: Our current team of around 60 members work in an interdisciplinary manner, with passion and creativity to advance our goal - because only together we can really make a difference!
Resolve Biosciences is applying the power of Molecular Cartography™ to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company's proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The platform offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program.
